<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01314586</url>
  </required_header>
  <id_info>
    <org_study_id>ADM Beneflax ISU-1</org_study_id>
    <nct_id>NCT01314586</nct_id>
  </id_info>
  <brief_title>Flax Lignans and Heart Health</brief_title>
  <acronym>ISULignan</acronym>
  <official_title>Iowa State Study on Flax Lignans and Heart Health</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Iowa State University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Archer Daniels Midland Co.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Iowa State University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Purpose: To demonstrate the efficacy of Beneflaxâ„¢ flaxseed lignan (SDG) concentrate to lower
      serum cholesterol levels.

      Background: Flaxseed has been studied for various health benefits in humans, including
      prostate health, glucose control, and cardiovascular health. Cholesterol levels and high
      blood pressure are known to be risk factors for cardiovascular disease. Whole flaxseed has
      had variable effects on serum lipid levels, perhaps a consequence of variations in the
      amounts of secoisolariciresinol diglucoside (SDG) found in different flax cultivars, making
      the study of this bioactive compound difficult.

      Hypothesis: Flaxseed lignan (SDG) extract (Beneflax) significantly lowers total and LDL
      cholesterol. Flaxseed lignans also lower blood pressure and fasting glucose levels.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2007</start_date>
  <completion_date type="Actual">November 2009</completion_date>
  <primary_completion_date type="Actual">July 2009</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in serum total cholesterol from baseline to 12 weeks after intervention treatments</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in serum glucose from baseline to 12 weeks after intervention treatments</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in blood pressure from baseline to end of treatment</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in serum clinical chemistry from baseline to end of treatment</measure>
    <time_frame>12 weeks</time_frame>
    <description>serum uric acid, BUN, Na, K, Cl, Ca, P, LDH, AST, ALT, bilirubin, carbon dioxide</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">93</enrollment>
  <condition>Hypercholesterolemia</condition>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo pill, diet counseling to comply with NCEP Step I diet</description>
  </arm_group>
  <arm_group>
    <arm_group_label>150 mg/day Beneflax</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2 pills taken at breakfast and dinner containing a total of 150 mg secoisolariciresinol (SDG) per day for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>300 mg/day Beneflax</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2 pills taken at breakfast and dinner containing a total of 300 mg secoisolariciresinol (SDG) per day for 12 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>secoisolariciresinol diglucoside-containing extract of flaxseed</intervention_name>
    <description>0, 150 or 300 mg/day as 2 pills taken at breakfast and dinner, dietary counseling to comply with NCEP Step I diet</description>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_label>150 mg/day Beneflax</arm_group_label>
    <arm_group_label>300 mg/day Beneflax</arm_group_label>
    <other_name>Beneflax</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men, 40-65 yrs/old, postmenopausal women 50-65 yrs/old not &gt; 5 yrs post menopause. All
             subjects were hypercholesterolemic with either total cholesterol &gt;240 mg/dl and &lt; 320
             mg/dL or LDL cholesterol &gt;140 mg/dl and &lt;190 mg/dl at the screening visit.

        Exclusion Criteria:

          -  Excluded subjects included diabetics, people being actively treated with niacins,
             fibrates, statins, insulin, ACE inhibitors or other cholesterol/ blood pressure
             pharmaceutical treatments, people who consumed large amounts of soy, flax, rye breads,
             pumpkin seeds, hydrolyzed milk products, sterols, and/or berries
             (strawberries/blueberries) or supplements aimed at cholesterol reduction such as
             spruce lignans, sytrinol (poly methoxylated flavanols), polycosinols, people consuming
             flaxseed on a regular basis.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Suzanne Hendrich, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Iowa State University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Nutrition &amp; Wellness Research Center</name>
      <address>
        <city>Ames</city>
        <state>Iowa</state>
        <zip>50011</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 9, 2011</study_first_submitted>
  <study_first_submitted_qc>March 11, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 14, 2011</study_first_posted>
  <last_update_submitted>March 11, 2011</last_update_submitted>
  <last_update_submitted_qc>March 11, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 14, 2011</last_update_posted>
  <responsible_party>
    <name_title>Suzanne Hendrich, PhD, University Professor</name_title>
    <organization>Iowa State University</organization>
  </responsible_party>
  <keyword>hypercholesterolemia</keyword>
  <keyword>postmenopause</keyword>
  <keyword>secoisolariciresinol diglucoside</keyword>
  <keyword>flaxseed</keyword>
  <keyword>lignans</keyword>
  <keyword>enterolactone</keyword>
  <keyword>enterodiol</keyword>
  <keyword>serum cholesterol</keyword>
  <keyword>LDL cholesterol</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypercholesterolemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Secoisolariciresinol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

